(EMAILWIRE.COM, June 07, 2018 ) Checkpoint Inhibitors Market was worth USD 6.08 billion in 2016 and is expected to reach USD 21.25 billion by 2021 with a CAGR of 28.4 %.

Checkpoint Inhibitors are drugs used in Immunotherapy. They are generally made up of antibodies that lead an immune system attack on cancer cells. T-cells launches an attack when it detects infected or Cancerous. Immune system uses a series of molecules called checkpoint molecules to protect normal cells from attack. Cancer cells use these Checkpoints to escape T-cells by arraying themselves with Normal Cells. Checkpoint Inhibitors block these proteins on cancer cells which lets T-Cells launch an attack on Cancer cells.

Browse full report @ https://www.marketdataforecast.com/market-reports/global-checkpoint-inhibitors-market-2177/

Rising Prevalence of cancer globally, and increasing funding and government support towards developing new drugs are some of the factors driving the growth of the market. However, high expense involved in R&D activities is one of the major factors restricting the growth of the market.

Request sample report @ https://www.marketdataforecast.com/market-reports/global-checkpoint-inhibitors-market-2177/request-sample

Checkpoint Inhibitors Market is segmented based on Drug type and Application. Based on Drug type, market is segmented into PD-1 inhibitors, PD-L1 inhibitors, CTLA-4, Chimeric Antigen Receptor T-cell, Others. Based on Application, market is segmented into Lung cancer, Renal cancer, Blood cancer, Bladder Cancer, Hodgkin lymphoma, Melanoma, Others. CTLA-4 Segment holds the highest share accounting for almost 94 % of the overall market. However, this segment is expected to lose some of its market to PD-1 inhibitors segment during the forecast period as majority of new treatments is based on PD-1 inhibitors.

Inquire before buying @ https://www.marketdataforecast.com/market-reports/global-checkpoint-inhibitors-market-2177/inquire

Geographically, market is further segmented into Asia-Pacific, Europe, Latin America, Middle east and Africa and North America. North America dominates the global market owing the relatively high clinical trials and funding available in this region. Asia-Pacific is the fastest growing region because of collaborations of international players with companies in this region.

Some of the key players in the checkpoint inhibitors market are Merck & Co., Inc., Bristol-Myers Squibb, Roche, AstraZeneca, Ono Pharmaceutical Co., Ltd., Juno Therapeutics, Novartis International AG, and Kite Pharma.

Buy full report @ https://www.marketdataforecast.com/cart/buy-now/global-checkpoint-inhibitors-market-2177

About Market Data Forecast:

Market Data Forecast is a firm working in the area of market research and business intelligence. With rich experience in research across various business domains, they cater to the needs of both individual and corporate clients. From all-encompassing umbrella markets to extremely specific niche markets covering all the major regions across the globe as part of the research scope, their research services offer one of a kind specialities with competitive pricing options. For more info kindly visit, www.marketdataforecast.com

Contact:

Abhishek Shukla

Sales Manager (International Business Development)

Market Data Forecast

Direct Line: +1-888-702-9626

Mobile: +91 998 555 0206

Mail: abhishek@marketdataforecast.com

Visit MarketDataForecast Blog @ http://www.marketdataforecast.com/blog/

View latest Press Releases of MDF @ http://www.marketdataforecast.com/press-releases

Contact Information:
Market Data Forecast.
Abhishek Shukla
Tel: +1-888-702-9626
Email us


----
This press release is posted on EmailWire.com -- a global newswire that provides Press Release Distribution Services with Guaranteed Results